HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A novel MitoNEET ligand, TT01001, improves diabetes and ameliorates mitochondrial function in db/db mice.

Abstract
The mitochondrial outer membrane protein mitoNEET is a binding protein of the insulin sensitizer pioglitazone (5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione) and is considered a novel target for the treatment of type II diabetes. Several small-molecule compounds have been identified as mitoNEET ligands using structure-based design or virtual docking studies. However, there are no reports about their therapeutic potential in animal models. Recently, we synthesized a novel small molecule, TT01001 [ethyl-4-(3-(3,5-dichlorophenyl)thioureido)piperidine-1-carboxylate], designed on the basis of pioglitazone structure. In this study, we assessed the pharmacological properties of TT01001 in both in vitro and in vivo studies. We found that TT01001 bound to mitoNEET without peroxisome proliferator-activated receptor-γ activation effect. In type II diabetes model db/db mice, TT01001 improved hyperglycemia, hyperlipidemia, and glucose intolerance, and its efficacy was equivalent to that of pioglitazone, without the pioglitazone-associated weight gain. Mitochondrial complex II + III activity of the skeletal muscle was significantly increased in db/db mice. We found that TT01001 significantly suppressed the elevated activity of the complex II + III. These results suggest that TT01001 improved type II diabetes without causing weight gain and ameliorated mitochondrial function of db/db mice. This is the first study that demonstrates the effects of a mitoNEET ligand on glucose metabolism and mitochondrial function in an animal disease model. These findings support targeting mitoNEET as a potential therapeutic approach for the treatment of type II diabetes.
AuthorsTakehiro Takahashi, Masashi Yamamoto, Kazutoshi Amikura, Kozue Kato, Takashi Serizawa, Kanako Serizawa, Daisuke Akazawa, Takumi Aoki, Koji Kawai, Emi Ogasawara, Jun-Ichi Hayashi, Kazuto Nakada, Mie Kainoh
JournalThe Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 352 Issue 2 Pg. 338-45 (Feb 2015) ISSN: 1521-0103 [Electronic] United States
PMID25503385 (Publication Type: Journal Article)
CopyrightCopyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.
Chemical References
  • Blood Glucose
  • CISD1 protein, human
  • DNA, Mitochondrial
  • Hypoglycemic Agents
  • Iron-Binding Proteins
  • Ligands
  • Membrane Proteins
  • Mitochondrial Proteins
  • PPAR gamma
  • Piperidines
  • ethyl 4-(3-(3,5-dichlorophenyl)thioureido)piperidine-1-carboxylate
  • mitoNEET protein, mouse
  • Thiourea
Topics
  • Animals
  • Blood Glucose (analysis)
  • DNA, Mitochondrial (metabolism)
  • Diabetes Mellitus, Experimental (drug therapy, metabolism, physiopathology)
  • Diabetes Mellitus, Type 2 (drug therapy, metabolism, physiopathology)
  • Escherichia coli (genetics)
  • Fluorescence Resonance Energy Transfer
  • Humans
  • Hypoglycemic Agents (administration & dosage, pharmacology, therapeutic use)
  • Iron-Binding Proteins (metabolism)
  • Ligands
  • Male
  • Membrane Proteins (metabolism)
  • Mice, Inbred Strains
  • Mitochondria, Muscle (drug effects, enzymology, physiology)
  • Mitochondrial Proteins (genetics, metabolism)
  • PPAR gamma (metabolism)
  • Piperidines (administration & dosage, pharmacology, therapeutic use)
  • Surface Plasmon Resonance
  • Thiourea (administration & dosage, analogs & derivatives, pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: